Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05784688 · ClinicalTrials.gov registry record · Phase 1

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

A Phase 1 study of Colorectal Cancer and Solid Tumor, sponsored by TiumBio Co..

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
11
Study locations

NCT05784688 is a Phase 1 study of Colorectal Cancer and Solid Tumor that is actively recruiting participants, run by TiumBio Co.. The registered enrollment target is 140 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05784688, a Phase 1 study of Colorectal Cancer and Solid Tumor, is actively recruiting participants, sponsored by TiumBio Co..

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
11
Study locations

Study Summary

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

Conditions Studied

Colorectal Cancer Solid Tumor Head and Neck Squamous Cell Carcinoma Biliary Tract Cancer

Interventions

  • DRUG TU2218 + KEYTRUDA® (Pembrolizumab)

Study Locations (11)

Other

  • CHA University Bundang Medical Center - Seongnam
  • Seoul National University Bundang Hospital - Seongnam
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital - Seoul
  • The Catholic University of Korea Seoul St. Mary Hospital - Seoul
  • The Catholic University of Korea St. Vincent's Hospital - Suwon

Texas

  • NEXT Oncology - San Antonio
  • Hope Cancer Center - Tyler

Washington

  • Medical Oncology - Spokane

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-03-10
Est. Completion 2028-12
Phase Phase 1

Sponsor

TiumBio Co.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05784688

The ClinicalTrials.gov registry entry for NCT05784688 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is TiumBio Co., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which TU2218 + KEYTRUDA® (Pembrolizumab) is the first listed.

NCT05784688 reports 11 study locations spanning 3 distinct geographic areas - top geographies include Other, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT05784688 about?

NCT05784688 is a clinical study titled "Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors". This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

What is the current status of trial NCT05784688?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-03-10. Estimated completion is 2028-12.

What conditions does trial NCT05784688 study?

This clinical trial studies the following conditions: Colorectal Cancer, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Biliary Tract Cancer.

What interventions are being tested in trial NCT05784688?

The interventions under investigation include: TU2218 + KEYTRUDA® (Pembrolizumab) (DRUG).

Who is sponsoring clinical trial NCT05784688?

This trial is sponsored by TiumBio Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05784688 being conducted?

This trial has 11 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.